Business
BELLUS Health announces oral and poster presentations highlighting Shigamab(TM) for the treatment of hemolytic uremic syndrome
LAVAL, QC , Sept. 9, 2015 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or th...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\nLAVAL, QC, Sept. 9, 2015 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today announced that the Company will present data from multiple clinical and pre-clinical studies evaluating BELLUS Health's rare disease drug candidate, Shigamab™, as a potential treatment for shiga-toxin E. coli induced hemolytic uremic syndrome (sHUS).  \n\nThe data will be presented at the International Symposium on Shiga toxin (verocytotoxin) Producing Escherichia Coli (VTEC) 2015 conference in Boston on September 14-16, 2015. \n\nShigamab™ is a monoclonal antibody therapy being developed for the treatment of sHUS, which principally affects the kidneys and often leads to acute dialysis, and in certain cases chronic kidney disease and death, primarily in children.  \n\n\"The promising data we will share with key opinion leaders attending the conference further validates our therapeutic approach for the treatment of sHUS and reinforces our commitment to develop a new potential treatment for patients affected by this condition,\" said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. \n\nOn Monday, September 14th, at 5:00 pm ET, Eduardo Luis Lopez, MD and Marta Contrini, MD, from the department of Pediatrics Hospital de Ninos \"Ricardo Gutierrez\", University of Buenos Aires, will deliver an oral presentation titled, `A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2 Administered Concomitantly to Children with Shiga Toxin-Producing Escherichia coli Infection and Bloody Diarrhea (SHIGATEC trial)'. \n\nOn Tuesday, September, 15th, DJ Stearns-Kurosawa, Ph.D., and Shinichiro Kurosawa, MD, Ph.D., from Boston University School of Medicine, will share a poster presentation titled, `Passive Immunity Strategy for Shiga Toxin-HUS in Non-human Primates'. \n\nOn Wednesday, September 16th, at 1:30 pm ET, Alison O'Brien, Ph.D., and Angela Melton-Celsa, Ph.D., from the Uniformed Services University of the Health Sciences Department of Microbiology and Immunology in Bethesda, MD, will deliver an oral presentation titled, 'Chimeric Shiga Toxin Type 2 (Stx2) Antibody (Shigamab™) Rescues Stx2a-Intoxicated Mice from Weight Loss or Kidney Injury When Administered up to 4 Days Post-Intoxication'. \n\nThe presentatio...